Galectin's GR-MD-02 For Fatty Liver Disease Treatment Receives US Patent

(RTTNews) - Galectin Therapeutics Inc. (GALT) Tuesday said U.S. Patent and Trademark Office issued patent for its carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis.

The FDA recently granted GR-MD-02 Fast Track designation for non-alcoholic steatohepatitis with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis. Galectin is currently conducting a Phase 1 clinical trial to evaluate the safety, tolerability and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02.

The major claims for the patent are for methods of obtaining galectin inhibitor compounds, obtaining a composition for parenteral or enteral administration in an acceptable pharmaceutical carrier and administering to a subject having at least one of the following, fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic hepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.